Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer
James Spicer(King's College London), Sophia N. Karagiannis(King's College London), Heike Lentfer(University of Hertfordshire), Giulia Pellizzari(King's College London), Chara Stavraka(King's College London), Bristi Basu(University of Cambridge), Kam Zaki(University College London Hospitals NHS Foundation Trust), Christopher Selkirk(University of Hertfordshire), Udai Banerji(Institute of Cancer Research), Joo Ern Ang(Royal Marsden NHS Foundation Trust), Katie Stoddart(Marks and Spencer (United Kingdom)), Heather J. Bax(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Atousa Khiabany(King's College London), Jitesh Chauhan(King's College London), Christopher J. Corrigan(King's College London), Amy Pope(Guy's Hospital), Mano Nakamura(King's College London), Kristina M. Ilieva(King's College London), Claire Barton(University of Hertfordshire), Annie Griffin(University of Southampton), Stephen J. Till(Guy's Hospital), Hannah J. Gould(King's College London), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Timothy Brier(Guy's and St Thomas' NHS Foundation Trust), Gareth J. Veal(Newcastle University), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Paul S. Jones(Cancer Research UK), George Nintos(Guy's and St Thomas' NHS Foundation Trust), Simon Carroll(Cancer Research UK), Sarah Mellor(Cancer Research UK), Ionut G. Funingana(University of Cambridge), Susan Brook(Marks and Spencer (United Kingdom)), Sarah E. Pinder(St Thomas' Hospital), Natalie Woodman(London Cancer)
Cited by 18
Related Papers
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Targeting folate receptor alpha for cancer treatment
|Oncotarget|2016|447